Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • ROOMS:

Algernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASH

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has received a Notice of Allowance for a patent around its work on chronic kidney disease.

Moreau tells Proactive the patent, which is titled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis”, is based around its kidney disease program with the drug NP-251 or Repirinast. This is the company’s first allowance notice received from the US patent office.

Contact Details

Proactive Canada

+1 604-688-8158

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.